Corporate Action Notice

Corporate Action Notice

Page 1 of 3

Section 1: Issuer information (mandatory)
Name of issuer Rua Bioscience Limited
Class of Financial Product Ordinary shares
NZX ticker code RUA
ISIN (If unknown, check on NZX
website)
NZRUAE0004S1
Name of Registry Computershare Investor Services Limited
Type of corporate action
(Please mark with an X in the relevant
box/es)
Share Purchase
Plan/retail offer
Renounceable
Rights issue or
Accelerated
Offer

Capital
reconstruction
Non-
Renounceable
Rights issue or
Accelerated
Offer

Call Bonus issue
Placement X
Record date NA
Ex Date (one business day before the
Record Date)
NA
Currency NZD
External approvals required before offer
can proceed on an unconditional basis?
No
Details of approvals required NA
Section 7: Placement
(delete full section if not applicable, or mark rows as N/A if not applicable)*
Number of Equity Securities to be
issued
11,280,843
Issue price per Equity Security $0.025
Maximum dollar amount of Equity
Securities to be issued
1

$282,021.08
Proposed issue date Thursday, 18 December 2025

1

Where the issue price per Equity Security is not fixed, and the number of Equity Securities to be issued is not known, the Issuer
should instead indicate the maximum dollar amount of Equity Securities to be issued.

2 of 3
Existing holders eligible to
participate
2

Y (limited)
Related Parties eligible to
participate
3

N
Basis upon which participation by
existing Equity Security holders will
be determined
Those existing eligible shareholders who applied for
oversubscriptions in relation to Rua’s 1 for 3 rights offer
announced 3 November 2025.
Purpose(s) for which the Issuer is
issuing the Equity Securities
To fund short-term and immediate business operating
funding requirements.
Reason for placement rather than a
pro-rata rights issue or an offer
under a Share Purchase Plan in
which the Issuer’s existing Equity
Security holders would have been
eligible to participate
Having offered all shareholders the opportunity to
participate in the rights offer, the placement shares
represent oversubscriptions in excess of the rights offer
amount.
Equity Securities to be issued
subject to voluntary escrow
Nil
Number and class of Equity
Securities to be issued that will be
subject to voluntary escrow and the
date from which they will cease to
be escrowed
NA
Section 8: Lead Manager and Underwriter (mandatory)
Lead Manager(s) appointed N
Name of Lead Manager(s) NA
Fees, commission or other
consideration payable to Lead
Manager(s) for acting as lead
manager(s)
Nil
Underwritten N
Name of Underwriter(s) NA
Extent of underwriting (i.e. amount
or proportion of the offer that is
underwritten)
NA
Fees, commission or other
consideration payable to
Underwriter(s) for acting as
underwriter(s)
NA

2
Issuers should answer Y if existing shareholders are eligible to participate even if their participation is subject to satisfaction of
eligibility criteria applying to the placement generally, such as the offer only being made to investors in certain jurisdictions or with a
certain status, such as wholesale, sophisticated or professional investors only.

3
Issuers should answer Y if there are no restrictions on participation by Related Parties as a result of their status as Related Parties
(i.e. restrictions on participation applying to the placement generally should be disregarded).

3 of 3
Summary of significant events that
could lead to the underwriting
being terminated
NA
Section 9: Authority for this announcement (mandatory)
Name of person authorised to make this
announcement
Paul Naske
Contact person for this announcement Paul Naske
Contact phone number 021 445 154
Contact email address paul.naske@ruabio.com
Date of release through MAP 16/12/2025